Plasma phospholipid and sphingolipid alterations in Presenilin1 mutation carriers: A pilot study

Manuscript Number: 

15-0948R1

Author(s): 
Randall J. Bateman, Tammie LS Benzinger, Belinda Brown, Pratishtha Chatterjee, Anne M. Fagan, Veer Gupta, Ian James, Wei L.F. Lim, Ralph N. Martins, Colin L. Masters, John C. Morris, Guanghou Shui, Stuart G. Snowden, Hamid R. Sohrabi, Kevin Taddei, Markus R. Wenk, Chengjie Xiong

Disclosures

Randall J. Bateman

  • Consulting Fees:
    Dr. Randal Bateman reports grants from the NIH and an Anonymous Foundation during the conduct of the study. Outside the submitted work, Dr. Bateman reports grants from the Alzheimer's Association, American Academy of Neurology, an Anonymous Foundation, AstraZeneca, the BrightFocus Foundation, the Cure Alzheimer’s Fund, The Glenn Foundation for Medical Research, Merck, the Metropolitan Life Foundation, the NIH, the NIA, NINDS, the DIAN Pharma Consortium (Biogen Idec, Elan Pharmaceuticals Inc., Eli Lilly and Co., Hoffman La-Roche Inc., Genentech Inc., Janssen Alzheimer Immunotherapy, Mithridion Inc., Novartis Pharma AG, Pfizer Biotherapeutics R and D, Sanofi-Aventi, Eisai), and the Ruth K. Broadman Biomedical Research Foundation. He reports non-financial support from Avid Radiopharmaceuticals, stock and part ownership of C2N Diagnostics. He has consulted for Roche, IMI, Sanofi, the Global Alzheimer's Platform, FORUM, Boehringer Ingelheim, Merck, and OECD.

Tammie LS Benzinger

  • Consulting Fees:
    Involved in clinical trials with Avid, Lilly and Roche; CME preparation with Quintiles and Medscape; Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly) and receives travel support from the National Multiple Sclerosis Society.

Belinda Brown

  • Nothing to Disclose

Pratishtha Chatterjee

  • Nothing to Disclose

Anne M. Fagan

  • Consulting Fees:
    Scientific advisory boards of IBL International and Roche and is a consultant for AbbVie.

Veer Gupta

  • Nothing to Disclose

Ian James

  • Nothing to Disclose

Wei L.F. Lim

  • Nothing to Disclose

Ralph N. Martins

  • Equity:
    Owns stocks in the biotech company Alzhyme.

Colin L. Masters

  • Consulting Fees:
    Dr. Colin Masters has provided consultation to Eli Lilly, Actinogen and Prana Biotechnology.
    Equity:
    He has stock ownership in Prana Biotechnology.

John C. Morris

  • Consulting Fees:
    Served as a consultant for Lilly USA, ISIS Pharmaceuticals, and Charles Dana Foundation. He receives research support from Eli Lilly/Avid Radiopharmaceuticals and is funded by NIH grants # P50AG005681; P01AG003991; P01AG026276 and U19AG032438.

Guanghou Shui

  • Nothing to Disclose

Stuart G. Snowden

  • Nothing to Disclose

Hamid R. Sohrabi

  • Consulting Fees:
    Dr. Hamid Sohrabi has previously received payments from Wyeth and Pfizer and is currently receiving remuneration for ongoing work as part of the Takeda TOMM40 Trial.

Kevin Taddei

  • Nothing to Disclose

Markus R. Wenk

  • Nothing to Disclose

Chengjie Xiong

  • Nothing to Disclose